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Abstract
Purpose of Review In this review, we highlight the most im-
portant cellular and molecular mechanisms that contribute to
cardiac inflammation and fibrosis. We also discuss the inter-
play between inflammation and fibrosis in various precursors
of heart failure (HF) and how suchmechanisms can contribute
to myocardial tissue remodelling and development of HF.
Recent Findings Recently, many research articles attempt to
elucidate different aspects of the interplay between inflamma-
tion and fibrosis. Cardiac inflammation and fibrosis are major
pathophysiological mechanisms operating in the failing heart,
regardless of HF aetiology. Currently, novel therapeutic op-
tions are available or are being developed to treat HF and these
are discussed in this review.
Summary A progressive disease needs an aggressive manage-
ment; however, existing therapies against HF are insufficient.
There is a dynamic interplay between inflammation and fibro-
sis in various precursors of HF such as myocardial infarction
(MI), myocarditis and hypertension, and also in HF itself.
There is an urgent need to identify novel therapeutic targets
and develop advanced therapeutic strategies to combat the
syndrome of HF. Understanding and describing the elements
of the inflammatory and fibrotic pathways are essential, and
specific drugs that target these pathways need to be evaluated.
Keywords Cardiac . Fibrosis . Inflammation .
Macrophages . HF . ECM .Heart
Introduction
Heart failure (HF) is a leading cause of morbidity and mortal-
ity worldwide and an important cause of hospitalization. It
severely reduces the quality of life of the affected and the 5-
year mortality rate is higher than that of most malignancies
[1–3]. Various types of cardiac insults culminate in the syn-
drome of HF, but inflammation and fibrosis are key patho-
physiological mechanisms operating in the failing heart.
These mechanisms affect the tissue architecture, electrical
conduction and mechano-electrical coupling and also have
direct deleterious effects on force generation by
cardiomyocytes [4].
In this review, we focus on important cellular and molecu-
lar mechanisms of cardiac inflammation and fibrosis, the in-
terplay between inflammation and fibrosis in various precur-
sors of HF such as myocardial infarction (MI), hypertension
and myocarditis and how persistence of such mechanisms
could enhance progression to chronic HF (CHF).
Furthermore, we provide insights into novel therapeutic op-




Inflammation is a physiological defence mechanism of the
body against injurious stimuli such as tissue damage and in-
fection. Timely inflammation in adequate intensity is essential
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to eliminate harmful stimuli; an insufficient inflammatory re-
sponse can result in persistence of the trigger. Active resolu-
tion of inflammation is also essential as it facilitates tissue
healing after injury; failure to resolve leads to chronic inflam-
mation, extended tissue destruction and progressive fibrosis
[5, 6]. Inflammation and fibrosis can thus be viewed as a
continuum of events within the framework of tissue defence,
repair and regeneration.
The inflammatory response is extremely complex and
comprises several stages including vascular phase, cellular
phase and resolution phase. Leukocytes are major cellular
effectors that direct this response through various mecha-
nisms, including chemical mediators such as cytokines [7].
During the inflammatory process, the endothelial layer under-
going activation and selective changes in permeability allows
cellular components to shift from intravascular to extravascu-
lar compartment [8]. Secreted proteins and extracellular ma-
trix (ECM) components also play a vital role in inflammation
by directly moderating the inflammatory cascade or by pro-
viding signals to cellular components of inflammation.
Osteopontin, a phosphorylated glycoprotein secreted by
monocytes and lymphocytes, mediates leukocyte adherence
and migration [9]. Versican is an ECM proteoglycan, also
involved in leukocyte adherence andmigration; it is abundant-
ly expressed and produced by activated macrophages and stro-
mal cells during inflammation [10]. Hyaluronic acid (HA) is a
glycosaminoglycan ECM component having a dual role in
inflammation. While native polymeric HA is typically anti-
inflammatory [11, 12], the smaller fragments elicit a pro-
inflammatory response by binding to toll-like receptor 2
(TLR2) and TLR4 of monocytes, dendritic cells and lympho-
cytes [13]; TLRs are a class of proteins that play a key role in
the innate immune system. Recent studies also indicate that
low molecular weight HA fragments promote a classically
activated “pro-inflammatory” state in macrophages [14].
Resolution of Inflammation
Resolution of inflammation is an active process orchestrated
by “pro-resolution” factors. These factors induce “pro-resolu-
tion” programmes in stromal cells and provide cues to inflam-
matory cells such as neutrophils to undergo apoptosis. They
also enhance efferocytosis and later signal macrophages to
exit via lymphatic vessels [6, 15••]. Polyunsaturated fatty
acid-derived resolvins and protectins function as proresolution
factors and play a key role in subduing inflammation [16, 17]
(Fig. 1). Inflammation is further modulated by a number of
checkpoints. For instance, TLR-mediated inflammasome ac-
tivation is countered by a negative internal feedback mecha-
nism involving phosphoinositide 3-kinase (PI3K) and exces-
sive TLR signalling is moderated by negative regulators of
immune responses, such as interleukin-1 receptor-associated
kinase-M (IRAK-M) and suppressor of cytokine signalling-1
(SOCS-1). T-regulatory cells also actively inhibit inflamma-
tion by producing several anti-inflammatory cytokines [18,
19]. Failure of such regulatory mechanisms could lead to a
state of chronic inflammation causing continuous tissue dam-
age and progressive fibrosis.
Fibrosis
Fibrosis is an essential component of tissue repair that follows
tissue injury and is usually associated with inflammation. The
aim of fibrosis is to deposit connective tissue in order to pre-
serve tissue architecture; progressive fibrosis reflects a patho-
logic state and results in scarring, impairment of function and
organ damage [5, 20].
Myofibroblasts are major cells responsible for ECM secre-
tion; they arise directly from fibroblasts or from other cell
types such as macrophages, endothelial cells, pericytes and
circulating monocytes. Several literature reviews exclusively
discuss the role of (myo)fibroblasts in fibrosis and interested
readers are directed to them [21, 22•].
Macrophages also play a pivotal role in secretion of ECM
components and in ECM remodelling. They are major sources
of matrix metalloproteinases (MMPs) and tissue inhibitor of
metalloproteinases (TIMPs) [23] and are the primary cells
involved in the phagocytosis of cellular debris and infectious
agents. The phagocytosed particle can influence phenotypic
characteristics of macrophages [24, 25]; for instance, macro-
phages assume a more fibrotic (M2) phenotype after ingesting
apoptotic neutrophils [26]. Cytokines such as interleukin-13
(IL13) and IL4 also induce profibrotic (M2) phenotypic
changes in naïve (M0) macrophages. M2 phenotype is char-
acterized by reduced expression and secretion of inflammato-
ry mediators, e.g. tumour necrosis factor-α (TNFα) and IL6,
and augmentation of cell survival and fibrotic signals, e.g.
IL10, insulin-like growth factor-1 (IGF1), transforming
growth factor-β (TGFβ) and galectin-3 (Gal-3) [27•, 28•].
Besides promoting fibrosis, M2macrophages also endocytose
collagen utilizing mannose receptors highlighting their pleio-
tropic role in ECM homeostasis [29]. Other immune cells, e.g.
neutrophils, lymphocytes and eosinophils, also contribute to
the development of fibrosis in various organs [7]. Extensive
communication between inflammatory cells, fibroblasts and
ECM actively modulates the fibrotic response [30–33].
Cardiac Inflammation
Virtually any cardiac insult, e.g. ischaemia and infection, can
initiate an inflammatory response in the heart; systemic in-
flammation can in itself trigger several inflammatory path-
ways within the cardiac tissue [34]. While acute cardiac in-
flammation, e.g. myocarditis, could result in rapid decline of
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cardiac function, chronic inflammation causes progressive
structural damage, leading to cardiac fibrosis.
The Role of Various Cell Types in Cardiac Inflammation
a. Immune cells as a source of cardiac inflammation:
Neutrophils and monocytes home to the site of cardiac injury
and release aggressivemediators such as reactive oxygen species
(ROS) and proteases, with the primary aim of eliminating the
factors that caused the cardiac insult. However, this nonspecific
response could also result in extensive damage to the healthy
cardiac tissue [35]. Macrophages exposed to inflammatory sig-
nals, e.g. Interferon-γ (IFNγ) and IL1, typically assume a pro-
inflammatory M1 phenotype [36]. These macrophages sustain
cardiac inflammation by secreting inflammatory cytokines them-
selves and can also signal neighbouring fibroblasts and
cardiomyocytes to adopt pro-inflammatory phenotypes [37]. In
subsequent stages of inflammation, effectors of innate immune
system are modulated by lymphocytes; for instance, cytokines
secreted from Th1 cells sustain inflammation while Th2 cyto-
kines produce anti-inflammatory and prohealing signals [38].
b. Pro-inflammatory cardiomyocytes in cardiac injury:
Cardiomyocytes (~30–40% of cells in the healthy heart) se-
crete pro-inflammatory cytokines typically after hypoxia or
cardiac injury [39•]. TNFα expression is upregulated in hyp-
oxic cardiomyocytes [40] while lipopolysaccharide (LPS)
stimulation of cardiomyocytes in vitro increases IL6 produc-
tion [39•]. IL6 and other related cytokines secreted by
cardiomyocytes are pivotal in regulating cardiac myocyte hy-
pertrophy and apoptosis [41]. Moreover, IL6 is known to di-
rect the nature of inflammation from acute to chronic, by
changing the leukocyte infiltrate from neutrophils to
monocyte/macrophages [42].
c. Cardiac fibroblasts as a source of pro-inflammatory cy-
tokines: Although mentioned frequently in the context of fi-
brosis, cardiac fibroblasts exposed to an inflammatory milieu,
Fig. 1 A simplified depiction of sequence of events in an inflammatory
response and the role of proresolution mediators in its termination. Tissue
injury elicits an initial vascular response, followed by an influx of
neutrophils and monocytes to the damaged area. After reaching the
tissue, monocytes transform into macrophages and actively phagocytose
the debris. Lymphocytes, which are cells of the adaptive immune system,
later modulate this initial response. The basic mechanisms of resolution of
inflammation are highlighted which are (1) lipid mediator class switching
producing proresolution molecules such as lipoxins and resolvins; (2)
increased efferocytosis by macrophages; (3) anti-inflammatory
cytokines secreted by “resolving” macrophages and regulatory T cells.
Failure to resolve leads to persistence of inflammation resulting in a
chronic inflammatory state, causing sustained tissue injury. Adapted
figure reproduced from [17] Buckley et al. 2014 with permission from
the authors. PGE2, prostaglandin E2; PGI2, prostacyclin
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e.g. TNFα, transform to a pro-inflammatory phenotype, with
increased expression of cytokines such as IL1β and IL6 [43].
When activated by mechanical stress, they produce pro-
inflammatory mediators such as monocyte chemoattractant
protein-1 (MCP-1), IL8 and biglycan [44••]. Cardiac fibro-
blasts also sustain and perpetuate pre-existing inflammation;
they directly facilitate transendothelial migration of leuko-
cytes by producing gelatinases such as MMP9. Co-culture of
fibroblasts with macrophages also increases macrophage in-
flammatory protein-1α (MIP-1α) expression in macrophages
and enhances reciprocal enhancement of monocyte-fibroblast
adhesion and chemokine production [30]. Furthermore, cardi-
ac fibroblasts stimulated by IL-17A produce chemokines such
as MCP-1, IL6 and leukaemia inhibitory factor (LIF), respon-
sible for recruiting and differentiating myeloid cells, and this
mechanism has been implicated in the pathophysiology of
inflammatory dilated cardiomyopathy (IDCM) [45].
Cardiac Inflammatory Pathways
TLRs are a part of the innate immune system and play a
crucial role in the development of inflammatory disorders by
initiating both innate and adaptive immune responses. They
are essentially pattern recognition receptors (PRRs) designat-
ed to recognize infectious or dangerous foreign patterns col-
lectively termed as pathogen-associated molecular patterns
(PAMPs) and danger-associated molecular patterns
(DAMPs) [46]. TLR4 is usually expressed in monocyte-
macrophage-lineage cells also in fibroblasts and epithelial
cells. Recent work by Liu and colleagues demonstrate upreg-
ulation of TLR4 in cardiomyocytes in HF [47••]. Lipid A
component is an important exogenous ligand for TLR4, while
various intracellular and extracellular components (e.g. heat
shock proteins (HSP), fibrinogen, heparin sulphate, HA) serve
as endogenous ligands [48]. Intracellular TLR4 signalling can
occur via both the myeloid differentiation primary response
gene-88 (MyD88)-dependent pathway resulting in early nu-
clear factor-κβ (NFκβ) activation or theMyD88-independent
pathway resulting in late NFκβ activation [49].
TNF-NFκβ pathways are indicated in cardiac infection and
injury, while viral triggers typically activate retinoic acid-
inducible gene-1 (RIG-1) pathways. Other cardiac inflamma-
tory mechanisms include caspase-1-inflammasome pathways,
activated usually during oxidative and cellular stress [50].
Persistent activation of various cardiac inflammatory path-
ways could serve as a precursor to fibrotic changes, resulting
in pathological remodelling of the heart.
Cardiac Fibrosis
Myocardial fibrosis can be classified as reactive interstitial
fibrosis, replacement fibrosis and perivascular fibrosis [22•].
Extensive cardiac fibrosis results in electro-mechanical distur-
bances and reduces nutrient supply toward the myocardium,
perpetuating a vicious cycle of fibrosis, cell death and inflam-
mation [51]. Herein, we briefly discuss the role of cardiac
fibroblasts, macrophages, angiogenesis and matricellular
components in cardiac fibrosis.
a. Cardiac myofibroblasts: Fibroblasts comprise up to 60–
70% of the cellular population in the heart. Activation of car-
diac fibroblasts to α-smooth muscle actin (α-SMA) express-
ing myofibroblasts is a crucial step toward fibrosis [39•].
Collagen-producing myofibroblasts typically develop after
cardiac injury and are programmed to undergo apoptosis after
carrying out their reparative “tissue-building” activities.
Persistence of myofibroblasts leads to progressive fibrosis
[52].
Sustained activation by mechanical stress or by profibrotic
molecules from neighbouring myofibroblasts and macro-
phages (e.g. TGFβ, Gal-3) results in transformation of quies-
cent fibroblasts into active collagen-producing myofibroblasts
[27•, 28•]. A recent study by Tian et al. revealed that sirtuin-6
(SIRT6) depletion in cardiac fibroblasts by SIRT6 siRNA in-
creased the expression ofα-SMA, resulting in a myofibroblast
phenotype [53]. Extensive work done by Herum and col-
leagues demonstrate for the first time, the involvement of
syndecan-4 in cardiac fibroblast-myofibroblast conversion
upon mechanical stress [54••]. Profibrotic properties of cardi-
ac fibroblasts are also potentiated by syndecans.
Overexpression of syndecan-4 in cardiac fibroblasts induces
overexpression of collagen, osteopontin and lysyl oxidase
(LOX) and is deemed to be a key player in the development
of passive myocardial stiffness in the pressure-overloaded
heart [54••].
Crosstalk between fibroblasts and cardiomyocytes is also
important in cardiac remodelling; myofibroblasts induce and
modify cardiomyocyte hypertrophy through such mecha-
nisms [55, 56]. Cardiac fibroblast-cardiomyocyte crosstalk
occurs via biochemical interactions involving paracrine fac-
tors such as TGFβ, angiotensin-II (Ang II) and interleukins.
Fibroblast-cardiomyocyte signal transduction also occurs via
electro-mechanical interactions utilizing gap junction proteins
such as connexins 43 and 45 or through biomechanical inter-
actions [22•, 57].
b. Cardiac macrophages and cardiac mast cells:
Macrophages are heterogenous and are phenotypically and
functionally diverse, and the M2 macrophage phenotype is
closely associated with fibrosis. Utilizing a mouse model of
hypertension, Falkenham and colleagues demonstrated that
M2 resident cardiac macrophages play a pivotal role in the
development of myocardial fibrosis [58]. Moriwaki et al. uti-
lized transgenic ApoE−/− mice that overexpressed urokinase-
type plasminogen activator (uPA) in macrophages. In compar-
ison to that of controls, their hearts were bigger and had a
significant amount of macrophage infiltration and increased
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collagen content. This effect was cardiac specific, as other
organs of transgenic mice did not display a higher amount of
inflammation and fibrosis in comparison to those of controls.
Plasminogen activator inhibitor-1 (PAI-1)-deficient mice also
developed exclusive fibrosis of the heart; fibrosis was absent
in the liver, spleen, lungs and kidneys. This suggests that
balance between uPA and its inhibitor PAI-1 is important in
homing of macrophages to the cardiac tissue and for the de-
velopment of cardiac fibrosis [59••]. Carlson et al. recently
demonstrated that in infarcted mice and human hearts, there
is a direct association between cardiac M2 macrophages and
fibrosis [60]. In this context, it is interesting to note that mac-
rophages do not usually undergo apoptosis and exit via lym-
phatic vessels. Thus, a well-functioning cardiac lymphatic
drainage is also of importance to curb fibrosis associated with
chronic inflammation [61].
Although a lot is not known about cardiac mast cells, they
appear to have a dual role in cardiac fibrosis. They tend to be
antifibrotic in the healthy heart and promote fibrosis in the
injured or diseased cardiac tissue [62, 63].
c. Role of angiogenesis: Impaired angiogenesis and insuf-
ficient neovascularization result in inadequate delivery of ox-
ygen and nutrients to the failing heart. Cardiomyocyte loss
follows, and a vicious cycle of oxidative stress, cell death
and fibrosis ensues [64]. In a rat model of HF after MI, treat-
ment with erythropoietin improved cardiac function by induc-
ing neovascularization [65]; in patients with acute MI, high
serum erythropoietin levels were associated with a smaller
infarct size [66]. Several therapeutic strategies that improve
angiogenesis are currently being developed to treat cardiac
fibrosis and HF [67, 68].
d. Matricellular components: The myocardial matrix is
very complex and dynamic. Myocardial matricellular pro-
teins, together with various regulatory proteins, are indicated
in the development or attenuation of cardiac fibrosis [69]. For
example, thrombospondins (TSP) are matrix glycoproteins
involved in cardiac remodelling occurring after cardiac stress
or injury. TSP1 is known to convert latent TGFβ to its active
form and is indicated extensively in cardiac remodelling [32,
70]. Frolova et al. demonstrated the important role of TSP4 in
reactive fibrosis caused by pressure overload to the heart in a
transverse aortic constriction (TAC) mouse model [71]. Other
matricellular components such as osteopontin and periostin
are also profibrotic and remain elevated in pathophysiological
scenarios such as MI and HF [31, 72]. Biglycan and decorin
are closely related ECM proteins belonging to the family of
small leucine-rich proteoglycans (SLRP) yet having different
properties with respect to cardiac remodelling and fibrosis.
Although biglycan is an indispensable player in adaptive re-
modelling after MI [73], ablation of this protein in the setting
of left ventricular pressure overload attenuates cardiac hyper-
trophy [74]. Extracellular decorin, however, has an antifibrotic
effect and inhibits the action of TGFβ on human cardiac
fibroblasts. Decorin also “reverses” adverse cardiac remodel-
ling in the failing human heart, highlighting its role in antag-
onizing cardiac fibrosis [75•].
ECM-cellular interactions are tightly regulated by modula-
tory proteins such as Gal-3 and syndecans. Gal-3 is a
matricellular glycan-binding protein involved in cardiac fibro-
sis and remodelling [76, 77••]. Activation of Gal-3 results in
its multimerization and formation of Gal-3 lattices on cellular
surfaces. Apart from critically regulating exchange of infor-
mation between cellular and extracellular compartments, Gal-
3 lattice can also amplify fibrotic signalling. A suggested
mechanism is lattice entrapment of TGFβ receptors, resulting
in amplification of profibrotic signalling pathways [33, 78].
Recent studies also indicate extensive interactions between
Gal-3 and various other ECM components such as sulphated
glycosaminoglycans and chondroitin sulphate, indicating Gal-
3 as a glycosaminoglycan-binding protein (GAGBP) [79].
However, further studies are needed to clarify if such interac-
tions also modulate ECM remodelling. Syndecans are cell-
associated transmembrane proteoglycans that are usually in-
volved in cell-matrix interactions. Syndecan-4 and syndecan-
1 are indicated extensively in cardiac fibrosis [80, 81].
Syndecan-1 amplifies Ang II–TGFβ signalling in angiotensin
II-mediated cardiac fibrosis via an unknown mechanism [82]
while syndecan-4 increases collagen cross-linking leading to
passive myocardial stiffness [54••].
Thus, it appears that ECM components together with mod-
ulatory proteins play a crucial role in the development and
resolution of the profibrotic response in the heart. Although
a substantial amount of information is known about ECM
signalling in fibrosis, there are still several missing links and
avenues for exploration (Fig. 2).
From Inflammation to Fibrosis in Major Scenarios
of Cardiac Injury
The sequel from inflammation to fibrosis in various cardiac
disease scenarios is different depending on the nature of car-
diac insult and its duration. A deeper understanding of the
mechanisms and succession of events could help us identify
possible therapeutic targets and increase treatment possibili-
ties. Herein, we discuss dominant scenarios of cardiovascular
injury, namely MI, myocarditis and hypertension, and how
persistence of inflammation could lead to progressive fibrosis
and HF.
Myocardial Infarction
MI usually occurs after a vascular insult to the myocardium
and is characterized by extensive necrosis of cardiomyocytes.
This results in leakage of intracellular contents and accumu-
lation of ROS. The released DAMPs together with cytokine
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signals from the neighbouring cells constitute the “alarmin-
response” [83]. However, the infarcted area has limited or no
vascularization, and this prevents the blood-borne immune
cells from gaining immediate access to the necrotic core.
During these initial stages of ischaemic damage, cardiac
myofibroblasts could potentially take over the phagocytic role
of macrophages, by actively engulfing dead cells [84].
This is followed by an intense and transient inflammatory
phase, characterized by a “neutrophil-monocyte” infiltration
[85]. However, both resident cardiac cells (cardiomyocytes,
cardiac fibroblasts, resident macrophages, mast cells) and re-
cruited cells (leukocytes) contribute to the development of
sterile inflammation post-MI [85, 86•]. The innate immune
cells recognize the released alarmins utilizing TLRs and acti-
vate downstream inflammatory pathways, and TLR2 and
TLR4 are crucial players in the post-infarct inflammatory
reaction.
Inflammation is further sustained by upregulation of vari-
ous pro-inflammatory cytokines, e.g. MCP-1, TNFα and IL6,
within the infarcted myocardium. MCP-1 is involved in the
recruitment of monocytes while TNFα enhances adhesion and
extravasation of leukocytes through the endothelium [87–89].
TNFα is an acute-phase protein involved in both post-MI
inflammatory reaction and ischaemia-reperfusion (I/R) injury
[90, 91•]. The role of IL6 in cardiac inflammation and remod-
elling is ambiguous. Enhanced IL6 expression could accentu-
ate the inflammatory response and exacerbate the deleterious
after-effects of MI [42, 56]. However, knocking out IL6 con-
fers no protective effect in a mouse model of MI [92].
Moreover, IL-6 receptor inhibition did not improve cardiac
function after I/R in a recent study [93]. There are also chang-
es in ECM around the necrotic area after MI. For instance,
large polymers of HA are degraded to low molecular weight
HA and together with fibronectin fragments initiate and sus-
tain a multitude of inflammatory cascades [94].
Molecular stop signals of inflammation such as IRAK-M in
macrophages and fibroblasts actively wean the post-MI in-
flammatory response. They prevent uncontrolled TLR/IL1-
mediated responses by acting as a functional decoy to attenu-
ate sustained inflammatory response and improve adverse
post-infarction cardiac remodelling [95].
In the proliferative phase that follows, macrophages secrete
several cytokine growth factors and activate mesenchymal
reparative cells to deposit ECM [85]; Gal-3, a profibrotic pro-
tein produced predominantly by macrophages, is a major
player in post-MI cardiac remodelling [27•, 77••, 96].
Fig. 2 Basic mechanisms of cardiac fibrosis highlighting the role of
regulatory proteins in profibrotic signal modulation. ECM matrix
deposition is the hallmark of fibrosis and myofibroblasts are the central
cells in ECM synthesis. M2 macrophages also play a crucial role in
fibrosis and influence ECM turnover chiefly by influencing MMP/
TIMP proportions. There is extensive communication between these
two cell types occurring through direct cell-cell interactions and also
through paracrine signalling. In this diagram, we emphasize the central
role of regulatory proteins, such as galectin-3 and syndecans, and how
they can directly moderate fibrotic signalling betweenmyofibroblasts and
M2 macrophages. However, little is known about the interaction of
regulatory proteins directly with ECM components and this could be
the focus of future research. Two commonly occurring fibrotic
scenarios in the heart are also depicted. In reactive fibrosis,
cardiomyocyte death is usually the consequence of fibrosis; while in
replacement fibrosis, cardiomyocyte death is the key driver of fibrosis.
ECM, extracellular matrix
240 Curr Heart Fail Rep (2017) 14:235–250
TGFβ, another key fibrotic cytokine, aids in repair by
supressing inflammation and stimulating hypertrophic cardio-
myocyte growth after MI. TGFβ also promotes ECM deposi-
tion by upregulating collagen and fibronectin synthesis and
downregulating ECM degradation [28•, 97]. Crosstalk be-
tween M2 macrophages and fibroblasts together with Th2
responses sustains the fibrotic response. Recent studies also
suggest the indispensable role of proteoglycans such as
syndecan-1 and 4 in post-MI remodelling and fibrosis of the
heart. Although mice lacking syndecan-1 and 4 showed
marked reduction in profibrotic signalling, this resulted in in-
creased cardiac rupture after MI [80, 81].
Apoptosis of the majority of reparative cells marks the end
of the proliferative stage and infarct maturation occurs with
the formation of cross-linked collagen. The extent of post-MI
remodelling depends on the infarct size and the quality of
cardiac repair. The infarct zone undergoes replacement fibro-
sis while the surrounding non-infarct zone displays
perivascular and interstitial fibrosis [98•]. The aim of the fi-
brotic response is to preserve structural integrity and to main-
tain the pump function of the heart by preventing dilatation,
aneurysm formation or myocardial rupture [99]. However,
failure of cardiac myofibroblasts to undergo apoptosis or per-
sistence of profibrotic signalling could result in pathological
remodelling of the heart.
Myocarditis—Inflammatory Cardiomyopathy
Viral infection is a common cause of myocarditis and is char-
acterized by inflammation of the myocardium; we discuss the
sequence of events from infection to fibrosis in group B
Coxsackie viral (CVB) infection.
Macrophages and lymphocytes of Peyer’s patches and the
spleen serve as ports of entry for CVB3 viral particles, and
they reach the heart through the bloodstream. Utilizing endo-
thelial receptor CAR (coxsackievirus and adenovirus recep-
tor), primarily located in the intercalated discs of the adult
heart or receptor DAF (delay accelerating factor), they trans-
locate into cardiomyocytes [100]. CAR-deficient mice are re-
sistant to both cardiac infection and inflammation, clearly
suggesting that in the acute phase of myocarditis, most of
the damage is mediated by the virus. Lindner et al. demon-
strated that when cardiomyocytes and cardiac fibroblasts were
both infected with CVB3, cardiac fibroblasts displayed a ten-
fold increase in viral replication, indicating their crucial role in
contributing to the viral load in myocarditis [101••].
TLR3 is involved in viral recognition and in mounting
antiviral type II interferon response; mice lacking TLR3 de-
veloped severe viral myocarditis highlighting the protective
action of this TLR in CVB3 infection [102]. After entering
the cardiomyocytes, the viral machinery is actively replicated.
Viral proteases such as enteroviral protease-2A cleave dystro-
phin and dystrophin-associated glycoproteins [103]. This
could result in the loss of tethering of the cardiomyocytes to
the ECM, leading to cardiomyocyte-ECM uncoupling [104].
Subsequent cardiomyocyte loss occurs via necrosis or apopto-
sis and is usually followed by replacement fibrosis. The viral
PAMPs and released cellular contents are also recognized by
other TLRs, and this leads to activation of other pro-
inflammatory cascades [100]. The role of inflammation-
induced damage in the acute phase is demonstrated by the fact
that TLR4-deficient mice were protected against CVB-
induced cardiac injury [105, 106••].
Role of the Innate and Adaptive Immune System
Infiltration of the heart by cells of the innate immune system
is the hallmark of the subacute phase. Natural killer (NK) cells
eliminate infected cells using cytotoxic proteins while mono-
cytes phagocytose dead cells. Macrophages maintain their M1
phenotype in the inflammatory milieu and produce copious
amounts of pro-inflammatory cytokines causing extensive tis-
sue damage. Susceptibility to infection with CVB in animal
models also appears to be sex dependent, with more severe
myocarditis in males. In line with this, hearts from male ani-
mals displayed a higher number of infiltrating M1 macro-
phages than female hearts. The cardiac inflammatory response
to infection was also enhanced whenM1macrophages, devel-
oped in vitro, were transferred into female mice. Conversely,
transferring the IL10-secreting M2 macrophages, developed
in vitro, into male animals inhibited cardiac disease [107].
This suggests the importance of macrophages in sex-
dependent effects of CVB-induced myocardial damage.
The cells from innate immune system are eventually re-
placed by those from the adaptive immune system in subse-
quent phases, and infected cardiomyocytes are eliminated by
CD8+ cytotoxic T cells. Severe combined immunodeficiency
(SCID) animal models displayed excessive damage to
cardiomyocytes by virus-mediated cardiac injury, highlighting
the importance of immune cells and inflammation in elimina-
tion of viral particles [108].
Cardiac repair and remodelling follow, once the inflamma-
tory trigger is removed. The dead tissue is replaced by a fi-
brotic scar facilitated by profibrotic signalling (e.g. TGFß) and
the reduction in cardiac function depends on the amount of
cardiomyocytes lost. However, incomplete clearance of the
cardiac viral load results in chronic inflammatory activation,
accelerating progression to dilated cardiomyopathy [100].
Although inflammation seems to play a crucial role in the
pathophysiology of myocarditis and its sequelae, broad-scale
immunosuppression fails to improve cardiac function in such
patients. The other mechanism by which chronic myocardial
damage can occur is through the development of autoimmune
myocarditis, and IL13 seems to offer protection against exper-
imental autoimmune myocarditis by moderating macrophage
differentiation [109].
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Pressure Overload—Hypertension
Although hypertension has a strong genetic component, neu-
rohormonal activation, oxidative stress and low-grade system-
ic inflammation play a vital role in its aetiology, especially in
insulin-resistant states. Hypertension is a leading cause of HF
and exerts a deleterious effect on the cardiovascular system
through direct haemodynamic mechanisms and also through
overactivation of the renin-angiotensin-aldosterone system
(RAAS) [110].
Hemodynamic parameters such as increased shear stress
together with low-grade systemic inflammation promotes en-
dothelial damage in hypertension. During the course of time,
this manifests itself as perivascular fibrosis with considerable
deposition of collagen in the adventitia of intramural arteries,
resulting in reduced vascular compliance and changes in per-
meability. Hypertension also elicits structural and functional
changes in microcirculation leading to microvascular remod-
elling and rarefaction [111].
There are also simultaneous changes in the cardiac tissue;
progressive deposition of collagen in cardiac ECM results in
reactive interstitial fibrosis. Although this develops without
cardiomyocyte loss, it decreases myocardial compliance and
clinically manifests as HF with preserved ejection fraction
(HFpEF) [112]. In advanced hypertension, there is a patholog-
ical hypertrophy of cardiomyocytes and also an increased loss
of cardiomyocytes. This results in irreversible replacement
fibrosis leading to deterioration of the systolic function of
the heart, clinically manifesting as HF with reduced ejection
fraction (HFrEF) [51, 110, 113]. In animal models of sudden
pressure overload (e.g. TAC), the results are more dramatic
with accelerated cardiomyocyte loss and more rapid onset of
cardiac fibrosis [114].
RAAS is the key homeostatic hormonal mechanism that
maintains blood pressure in order to ensure adequate tissue
perfusion. However, stimulation of the RAAS also elicits
pro-inflammatory and profibrotic responses and contributes
to cardiovascular remodelling. For instance, aldosterone has
been implicated in the development of cardiac fibrosis in hy-
pertension [115]; renin overexpression in hypertensive rats
leads to cardiac remodelling and diastolic dysfunction via a
fibrosis-independent “titin-related” mechanism [116].
As Ang II is the key vasoconstrictive protein in this axis,
we briefly discuss few novel mechanisms of Ang II-related
cardiovascular remodelling. Ang II can act both independent-
ly and via the classic TGFβ axis to induce fibrosis [117].
Recent studies describe the Ang II-Gal-3-IL6 axis as a modi-
fiable fibrotic pathway in hypertension. Genetic inhibition of
IL6 resulted in reduction of cardiac inflammation and fibrosis
in an Ang II high-salt-induced hypertension mouse model.
IL6 deletion also improved cardiac dysfunction although there
was no net reduction in blood pressure [118••], suggesting the
critical role of IL6 in the mediation of cardiac inflammatory
and fibrotic effects of Ang II. Subsequent studies in models of
chronic Ang II-induced hypertension demonstrated that genet-
ic ablation of Gal-3 also reduced myocardial macrophage in-
filtration and fibrosis, highlighting the causative role of Gal-3
in cardiac fibrosis related to hypertension [119]. ECMproteins
such as osteopontin are also involved in Ang II-induced car-
diac fibrosis, and studies with osteopontin−/− mice indicate
that there is a significant reduction in cardiac fibrosis after
3 weeks of Ang II infusion [120]. Other experimental studies,
also with murine models, suggest that syndecan-1 amplifies
profibrotic effects of Ang II and is a critical regulator of fibro-
sis in the heart [82]. Recently, neutrophil-generated S100a8/
S100a9 proteins have been implicated in Ang II-induced car-
diac inflammation and fibrosis [121]. There is also accumu-
lating evidence on the role of cardiac mast cell-IL4 axis in the
mediation and development of hypertension-related cardiac
fibrosis [63]. Targeting these novel pathways of inflammation
and fibrosis could effectively prevent or reduce cardiovascular
fibrosis in the setting of hypertension.
Heart Failure
Although most patients survive the primary cardiac event due
to early detection and timelymanagement, every cardiac insult
decreases the cardiac contractile reserve and these patients
have an increased risk of developing HF [122]. HF can be
defined as the inability of the heart to adequately maintain
cellular perfusion under normal cardiac filling pressure.
While half of the patients with HF exhibit decreased ejection
fraction (HFrEF), the other half have a normal EF (HFpEF).
Based on clinical presentation, HF can be classified as acute
HF (AHF), when the patient presents with cardiac decompen-
sation, and CHF, when the patient has impaired cardiac func-
tion but is compensated and stable, i.e. able to maintain tissue
perfusion without assistance [123, 124].
AHF is characterized by a systemic inflammatory response,
with elevated pro-inflammatory cytokines [125]. Other trig-
gers may be present that provoke inflammation: AHF is often
accompanied by viral or bacterial infection and is usually pre-
ceded by MI or atrial fibrillation (AF). However, after the
acute event has been treated, a chronic response develops,
and such patients frequently develop CHF. Other concomitant
factors such as hypertension can also contribute to the devel-
opment of AHF and CHF. It is also important to note that CHF
can itself be a predisposing factor for the development of
future AHF, and the goal of CHF management is to maintain
the patient in compensated HF state and prevent them from
deteriorating into a state of acute decompensated HF (ADHF)
[124].
Inflammation in the setting of CHF can be very complex.
Low-grade systemic inflammation can both be a cause and
consequence of HF [34, 126–128]. Moreover, chronic oxida-
tive stress associated with HF can exacerbate the pre-existing
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inflammatory state [129]. It is hypothesised that the presence
of co-morbidities might lead to increased inflammation and to
HF [130•]. There is also upregulation of TLR4 in
cardiomyocytes during HF, suggesting the direct role of
cardiomyocytes in cardiac inflammation associated with HF
[47••]. Sustained activation of protective neurohormonal
mechanisms can also contribute to ongoing cardiac inflamma-
tion and fibrosis [131, 132••], resulting in further loss of car-
diac function and clinical deterioration up to the point of
ADHF and death.
Thus, it is highly relevant to address this question in pa-
tients with CHF: Is cardiac fibrosis progressive? Serial bio-
marker measurements and imaging modalities such as cardiac
magnetic resonance imaging (CMR) can help us answer this
question by aiding in identifying patients with progressive
cardiac fibrosis [133–135] (Fig. 3).
Diagnosing and Monitoring Inflammation
and Fibrosis
Circulating biomarkers are biological markers detected in
blood or urine that ideally reflect biochemical and
(patho)physiological processes occurring in (injured) organs;
they are used as an adjunct in diagnosis, prognosis and risk
stratification, and also in optimizing treatment guidance [135,
136•]. Herein, we discuss the utility of biomarkers and imag-
ing techniques in monitoring cardiac inflammation and
fibrosis.
Inflammatory markers such as C-reactive protein (CRP)
and IL-6 can be used to predict cardiovascular diseases and
severity of HF while fibrotic markers such as Gal-3 and
syndecan-1 are currently used for risk stratification in HF
[137], predicting mortality [138] or readmission [139]. Serial
biomarker measurements, after taking biological variability
into account, could aid inmonitoring the “temporal dynamics”
of cardiac pathophysiological processes, thereby offering ad-
ditive prognostic value [134, 135].
Utilizing circulating biomarkers to predict ongoing myo-
cardial fibrosis could be difficult as circulating levels might
not reflect ECM deposition specifically in the cardiac tissue.
Their correlation with the gold standard “endomyocardial bi-
opsy” is therefore necessary to validate them as a biomarker of
myocardial fibrosis; out of a wide array of cardiac fibrosis
markers, procollagen 3N-terminal peptide (P3NP) and
carboxy-terminal propeptide of type 1 procollagen (P1CP)
appear to have a strong correlation with histologically proven
myocardial fibrosis. Lately, CMR has become the gold stan-
dard in the evaluation of cardiac fibrosis, and fibrotic bio-
markers are now compared with T1-weighted contrast-en-
hanced CMR images [140].
Imaging can itself serve as a biomarker of cardiac inflam-
mation and fibrosis. For instance, a T2-weighted image allows
detection of oedema and cardiac inflammation during acute
phases of myocarditis [141]. T1-weighted images with de-
layed contrast enhancement (DCE) using gadolinium can
be employed to visualize inflammatory infiltrate and re-
gional fibrosis, e.g. after MI [142]. However, such tech-
niques lose their discriminatory power to detect diffuse
interstitial fibrosis, e.g. in diabetic or hypertensive cardio-
myopathy, and CMR T1 mapping is the preferred modality
in such scenarios [143].
Information about cellular, molecular and metabolic
events occurring in the heart can be obtained with a func-
tional positron emission tomography (PET) scan. PET can
be used to monitor myocardial metabolism using radio-
tracers such as 18F-fluorodeoxyglucose (FDG) and also to
image and measure myocardial perfusion and blood flow
using various PET-myocardial perfusion imaging (PET-
MPI) tracers. Visualization of activated macrophages in
biologically active atherosclerotic plaques or in other sce-
narios is also possible using this imaging technique [144••,
145]. Furthermore, PET can detect diffuse fibrosis; for ex-
ample, it can be used to calculate the fraction of myocar-
dium perfusable by water, termed perfusable tissue index
(PTI). Fibrotic myocardium is unable to exchange water
rapidly; hence, a decline in PTI correlates directly with
the amount of fibrosis. A combination of myocardial me-
tabolism and perfusion could also identify myocardial fi-
brosis more precisely. Finally, PET technology has also
been harnessed to develop new HF drugs [144••].
Therapeutic Options
Pathological cardiac remodelling can be targeted in several
ways [146] but most strategies do not, or do not specifical-
ly target inflammation and fibrosis. When targeting cardiac
inflammation or fibrosis, the timing of therapy will be cru-
cial. For instance, reduction of myocardial inflammation in
the initial phases of MI or during the early phases of is-
chaemia-reperfusion injury could potentially yield better
outcomes [91•]. However, premature attenuation of fibro-
sis, e.g. during the onset of the proliferative phase, could
result in cardiac rupture or aneurysm formation [147,
148•].
In myocarditis, chronic inflammation has been held re-
sponsible for long-term effects leading to dilatation, and car-
diacmacrophages have been implicated in the aetiology [107].
However, broad-scale immunosuppression fails to improve
cardiac function in such patients [149]; utilizing compounds
that enhance resolution might counter the chronic inflamma-
tion in such cases [17]. Addressing autoimmune mechanisms
could be yet another approach to curb the progression of sub-
clinical disease to overt dilated cardiomyopathy.
Curr Heart Fail Rep (2017) 14:235–250 243
In hypertension, in addition to the existing therapy,
targeting the Ang II-Gal-3-IL6 axis or the mast cell-IL4 axis
using Gal-3 inhibitors or IL4 inhibitors could specifically re-
duce cardiac fibrosis [63, 118••, 119]. Therapeutic interven-
tions that focus on the quality of collagen in HF could also
significantly increase cardiac compliance. Excessively cross-
linked collagen is difficult to degrade and critically affects
ECM turnover. Syndecan-4-osteopontin-LOX axis is impor-
tant in the formation of insoluble cross-linked collagen [31,
54••], and therapeutic strategies that target such pathways
could also ameliorate the effects of myocardial fibrosis.
Further strategies to modulate ECM deposition are also
currently being developed [146]. Modalities enhancing titin-
compliance [150] and therapeutic angiogenesis [65, 67, 68]
could also be employed alongside improving cardiac function
in HF. This field is rapidly evolving and in the coming decade


































Fig. 3 The interplay between systemic inflammation, cardiac
inflammation and heart failure (HF) is highlighted. HF can arise de
novo, for instance after myocardial infarction (MI) or can result from
exacerbation of pre-existing HF. Long-standing systemic diseases such
as hypertension, diabetes mellitus (DM) or obesity can also adversely
affect cardiac function through various mechanisms (outside the
rectangular box). HF is a systemic inflammatory state and promotes
cardiac inflammation. Inflammation can affect cardiac function through
several mechanisms such as (A) reduced contractility affecting
mechanical properties of the heart, (B) cardiac stress leading up to
cardiomyocyte death and (C) cardiac fibrosis. All these effects lead to
HF or exacerbate pre-existing HF, and this is illustrated within the
rectangular framework. Biomarkers and imaging can aid us in
identifying the HF process early in the disease course and in assessing
the nature of HF to choose appropriate therapeutic interventions. AHF,
acute heart failure; ADHF, acute decompensated heart failure
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Conclusions
Cardiac inflammation and fibrosis are major pathophysio-
logical mechanisms operating in the failing heart irrespec-
tive of the aetiology of HF. There is a dynamic interplay
between inflammation and fibrosis in various precursors of
HF such as MI, myocarditis and hypertension, and also in
HF itself. Early diagnosis of HF with biomarkers and im-
aging is warranted; while CMR is useful for evaluating the
extent of injury, serial biomarker measurements indicate if
inflammation and fibrosis are progressive. A progressive
disease needs an aggressive management; however, existing
therapies against HF are insufficient. There is an urgent
need to identify novel therapeutic targets and develop ad-
vanced therapeutic strategies to combat the syndrome of
HF. To this end, exact spatio-temporal description of the
elements of the inflammatory and fibrotic pathways is es-
sential, and specific drugs that target these pathways need to
be evaluated.
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